H8627

Hydroxyurea

Name: Hydroxyurea
Brand: SIGMA

98% (elemental analysis), powder, RNR inhibitor

Synonym(s):

Hydroxycarbamide

Select a Size

All Photos(4)

About This Item

Linear Formula:

NH₂CONHOH

CAS Number:

127-07-1

Molecular Weight:

76.05

NACRES:

NA.77

PubChem Substance ID:

24278474

UNSPSC Code:

12352200

EC Number:

204-821-7

MDL number:

MFCD00007943

Beilstein/REAXYS Number:

1741548

Product Name

Hydroxyurea, 98%, powder

InChI key

VSNHCAURESNICA-UHFFFAOYSA-N

InChI

1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

SMILES string

NC(=O)NO

assay

98%

form

powder

color

white

solubility

H₂O: 50 mg/mL

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... CA1(759), CA2(760), CYP1A2(1544), RRM1(6240), RRM2(6241), RRM2B(50484)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Application

Hydroxyurea has been used:

for cell cycle synchronization in MCF-7 human breast carcinoma cells, Schizosaccharomyces pombe, primary root of seedling
as a drug for treating the parasite Leishmania mexicana in cell viability and cell cycle assay
as an inhibitor in the cell adhesion and motility assay in Caki control and CD9 knockdown cells

Biochem/physiol Actions

Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

General description

Hydroxyurea is a hydroxylated analog of urea. It is beneficial in increasing fetal hemoglobin (HbF) levels, which in turn reduces the frequency of severe crises and the need for blood transfusions in sickle cell anemia patients. Hydroxyurea exhibits cell-cycle specificity for the S phase, leading to cell arrest at G1 to S. This non-alkylating S phase-specific myelosuppressive agent has a mechanism of action that is not specific to platelets.

pictograms

GHS08

signalword

Danger

hcodes

H340,H361

pcodes

P201 - P308 + P313

Hazard Classifications

Muta. 1B - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma

Garner JM, et al.

Biochemical and Biophysical Research Communications, 471(1), 21-25 (2016)

Activity of hydroxyurea against Leishmania mexicana

Martinez-Rojano H, et al.

Antimicrobial Agents and Chemotherapy, 52(10), 3642-3647 (2008)

Protein tyrosine nitration in the cell cycle

Jia M, et al.

Biochemical and Biophysical Research Communications, 413(2), 270-276 (2011)

Flow cytometric chromosome sorting in plants: the next generation

Vrana J, et al.

Methods, 57(3), 331-337 (2012)

Hydroxyurea Toxicity

Jinna S and Khandhar PB

StatPearls [Internet] (2019)

View All Related Papers